%0 Journal Article
%A Haselmann, Verena
%A Gebhardt, Christoffer
%A Brechtel, Ingrid
%A Duda, Angelika
%A Czerwinski, Claudia
%A Sucker, Antje
%A Holland-Letz, Tim
%A Utikal, Jochen
%A Schadendorf, Dirk
%A Neumaier, Michael
%T Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.
%J Clinical chemistry
%V 64
%N 5
%@ 1530-8561
%C Washington, DC
%I American Association for Clinical Chemistry
%M DKFZ-2018-01849
%P 830 - 842
%D 2018
%Z 317
%X The current standard for determining eligibility of patients with metastatic melanoma for BRAF-targeted therapy is tissue-based testing of BRAF mutations. As patients are rarely rebiopsied, detection in blood might be advantageous by enabling a comprehensive assessment of tumor mutational status in real time and thereby representing a noninvasive biomarker for monitoring BRAF therapy.In all, 634 stage I to IV melanoma patients were enrolled at 2 centers, and 1406 plasma samples were prospectively collected. Patients were assigned to 3 separate study cohorts: study 1 for assessment of circulating tumor DNA (ctDNA) as part of companion diagnostics, study 2 for assessment of ctDNA for patients with low tumor burden and for follow-up, and study 3 for monitoring of resistance to BRAF inhibitor (BRAFi) or mitogen-activated protein kinase inhibitor therapy.Overall, a high degree of concordance between plasma and tissue testing results was observed at 90.9
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:29483107
%R 10.1373/clinchem.2017.281543
%U https://inrepo02.dkfz.de/record/141330